

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

AMNEAL PHARMACEUTICALS LLC and  
PAR PHARMACEUTICAL, INC.

Petitioners

v.

JAZZ PHARMACEUTICALS, INC.

Patent Owner

---

CASE IPR: Unassigned

Patent 8,731,963

---

**DECLARATION OF ROBERT J. VALUCK, Ph.D., R.Ph.**

PAR1007

*Inter Partes Review of USPN 8,731,963  
Declaration of Robert J. Valuck, Ph.D., R.Ph. (Exhibit 1007)*

**TABLE OF CONTENTS**

I.	Overview.....	1
II.	My background and qualifications .....	6
III.	Person of ordinary skill in the art .....	11
IV.	State of the art.....	12
V.	The '963 patent and its claims .....	16
	A. Claim 1 .....	17
	B. Claims 2-22 .....	21
	C. Claim 23 .....	26
	D. Claim 24 .....	27
	E. Claim 25 .....	27
	F. Claims 26-28 .....	28
	G. Orange Book listing of the '963 patent .....	28
VI.	A POSA exercising reasonable diligence would have located the Advisory Committee Art. ....	29
VII.	Basis of my analysis with respect to obviousness .....	30
	A. A POSA reading the ACA would have had a reason and the know-how to arrive at the computer-implemented methods of claims 1-7 & 9-23.....	30
	1. Claim 1 .....	32
	(a) Preamble .....	32
	(b) Claim 1, element 1.1 .....	40
	(c) Claim 1, elements 1.2-1.4.....	47
	(d) Claim 1, element 1.5.....	55

*Inter Partes Review of USPN 8,731,963  
Declaration of Robert J. Valuck, Ph.D., R.Ph. (Exhibit 1007)*

(e)	Claim 1, element 1.6.....	59
(f)	Claim 1, elements 1.7-1.8.....	61
2.	Claim 2.....	67
3.	Claim 3.....	68
4.	Claim 4.....	69
5.	Claim 5.....	70
6.	Claim 6.....	70
7.	Claim 7.....	71
8.	Claim 9.....	71
9.	Claim 10.....	73
10.	Claim 11.....	73
11.	Claim 12.....	74
12.	Claim 13.....	75
13.	Claim 14.....	75
14.	Claim 15.....	78
15.	Claims 16-19.....	78
16.	Claim 20.....	79
17.	Claims 21-22.....	81
18.	Claim 23.....	81
B.	Claims 8 and 24-28 would have been obvious over the ACA in view of Korfhage.....	104
1.	Claim 8.....	105
2.	Claim 24.....	107

*Inter Partes Review of USPN 8,731,963  
Declaration of Robert J. Valuck, Ph.D., R.Ph. (Exhibit 1007)*

3.	Claim 25 .....	130
4.	Claims 26-28 .....	131
VIII.	Secondary considerations of non-obviousness .....	131
A.	No commercial success .....	132
B.	No long-felt but unmet need or failure of others.....	133
C.	No failure of others.....	135
D.	Copying .....	136
E.	No unexpected superior results .....	136
IX.	Conclusion .....	137

*Inter Partes Review of USPN 8,731,963  
Declaration of Robert J. Valuck, Ph.D., R.Ph. (Exhibit 1007)*

I, Robert J. Valuck, do hereby declare as follows:

**I. Overview**

1. I am over the age of 18 and otherwise competent to make this declaration. This declaration is based on my personal knowledge as an expert in the fields of drug safety, drug abuse prevention, and prescription drug distribution. I understand that this declaration is being submitted together with a petition for *Inter Partes* Review (“**IPR**”) of claims 1-28 of U.S. Patent No. 8,731,963 (“**the ’963 patent**”) (PAR1001.)

2. I have been retained as an expert witness on behalf of Par Pharmaceutical, Inc. (“**Par**”) for this IPR. I am being compensated for my time in connection with this declaration at my standard consulting rate. I have no personal or financial interest in the outcome of this proceeding.

3. I understand that the ’963 patent issued on May 20, 2014, and resulted from U.S. Ser. No. 13/592,202, filed on August 22, 2012. I also understand that the U.S. Patent and Trademark Office (“**USPTO**”) records state that the ’963 patent is currently assigned to Jazz Pharmaceuticals, Inc. (“**Jazz**”).

4. The face page of the ’963 patent lists other patent applications. I understand that the ’963 patent is related to a patent application which was filed on December 17, 2002.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.